Recent research has established that Insulin-like Growth Factor 2 mRNA Binding Protein 3 (IGF2BP3) RNA-binding protein is involved in leukemia development, particularly in the KMT2A-translocated B-acute lymphoblastic leukemia (B-ALL) subtype.
In a recently published study, researchers from the University of Pennsylvania and collaborators aimed to identify compounds with high affinity to α-synuclein aggregates and high selectivity toward pathological α-synuclein compared to other brain targets.
Gynecological cancers with amplifications in the CCNE1 gene, which encodes cyclin E1, usually exhibit resistance to standard therapies. Since cyclin-dependent kinase 2 (CDK2) is the primary partner of cyclin E, CDK2 inhibitors represent a potentially effective treatment strategy for these malignancies.
Researchers from Excellamol Inc. presented the design and preclinical characterization of XM161-SN38, a novel IL-13Rα2-targeting polypeptide-drug conjugate being evaluated for the treatment of gliomas.
Kinnate Biopharma Inc. and affiliated organizations recently reported preclinical data for the novel brain-penetrant combination therapy using the MEK inhibitor KIN-7136 and the RAF inhibitor KIN-8391, as a novel therapeutic strategy for the treatment of melanoma brain metastasis.
Changchun Genescience Pharmaceuticals Co. Ltd. has reported GSC-000829, a novel and selective FGFR2/FGFR3 inhibitor being developed for the potential treatment of cancer.
Hangzhou Synrx Therapeutics Biomedical Technology Co. Ltd. recently presented the development and characterization of a novel PARG inhibitor, SYN-608, for the potential treatment of tumors with/without homologous recombination deficiency (HRD).
Targeted protein degradation has gained attention in recent years due to its potential to hit proteins that are difficult to engage with conventional small molecules. Pin1 is an enzyme associated with tumor formation overexpressed in pancreatic cancer cells or cancer-associated fibroblasts in particular.
MBT-C101 is a selective, potentially first-in-class potent HSP90 chaperone-mediated degrader of PI3Kα, for the treatment of breast cancer. It was developed by Magicbullet Therapeutics Inc. using the company’s Chaperone-mediated Degrader (CM-Degrader) platform.
RSS
